Evaluating Modes of Influenza Transmission (EMIT-2): Insights from a Controlled

Human Influenza Virus Infection Transmission Trial (CHIVITT)

Jianyu Lai[1], Hamed Sobhani[2], Kristen K. Coleman[1], S.-H. Sheldon Tai[1], Filbert Hong[1], Isabel

Sierra Maldonado[1], Yi Esparza[1], Kathleen M. McPhaul[1], Shengwei Zhu[2], Don L. DeVoe[2,3],

Justin R. Ortiz[4], Shuo Chen[5], Temima Yellin[6], Juan Manuel Carreno[6], Florian Krammer[6-9],

Benjamin J. Cowling[10], Aubree Gordon[11], Wilbur H. Chen[4], Jelena Srebric[2], and Donald K.

Milton[1,3*] for the EMIT-2 Study Team[†]

[1] Department of Global, Environmental, and Occupational Health, School of Public Health,

University of Maryland, College Park, MD, USA

[2] Department of Mechanical Engineering, University of Maryland, College Park, MD, USA

[3] Fischell Institute for Biomedical Devices, University of Maryland, College Park

[4] Center for Vaccine Development and Global Health, University of Maryland School of

Medicine, Baltimore, MD, USA

[5] Department of Epidemiology and Public Health, University of Maryland School of Medicine,

Baltimore, MD, USA

[6] Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

[7] Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount

Sinai, New York, NY, USA

[8] Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at

Mount Sinai, New York, NY, USA

[9] Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University

of Vienna, Vienna, Austria

[10] School of Public Health, The University of Hong Kong, Hong Kong Special Administrative

Region, China

[11] School of Public Health, University of Michigan, Ann Arbor, MI, USA

*Dr. Donald K. Milton, University of Maryland School of Public Health, 4200 Valley Drive,

College Park, MD 20742, USA email: dmilton@umd.edu; phone: 301-405-0389

†A complete list of EMIT-2 Study Team members is provided in S1 Text.

Abstract

A previous controlled human influenza transmission trial produced minimal transmission using

nasal inoculation of an egg adapted virus. Therefore, we implemented a new trial with naturally

infected Donors. We recruited healthy Recipients for four, two-week hotel quarantine cohorts

and naturally infected, qRT-PCR confirmed Donors for two cohorts. Five Donors (mean age: 21;

80% female; two H1N1, three H3N2, one for cohort 24b and 4 for 24c, Jan-Feb 2024) exposed

Recipients (mean age: 36; 55% female, eight in cohort 24b and 3 in 24c) in a hotel room with

limited ventilation but a high air recirculation rate. We collected exhaled breath, ambient and

personal bioaerosols, fomite swabs, and sera, and analyzed samples using dPCR and fluorescent

focus assays, hemagglutination inhibition (HAI) assay, and enzyme-linked immunosorbent assay

(ELISA). Compared with previously studied community-acquired influenza cases, we detected

viral RNA (44%) and culturable virus (6%) less frequently and measured fewer viral RNA

copies ($79 - 8.9 \times 10^3$ copies/30-min) in Donors' exhaled fine aerosols. One of 23 surface swab

samples was culture positive. At admission, 8 of 11 Recipients had HAI titers ≤ 10 but 9 of 11

had stronger binding antibody responses than Donors against vaccine strains corresponding to

Donor viruses. No Recipient developed influenza-like illness, PCR-positive respiratory samples,

or serological evidence of infection. Potential explanations and insights regarding lack of

transmission include importance of cough and seasonal variation in viral aerosol shedding by

Donors, of potential cross-reactive immunity in middle-aged Recipients with decades of

exposure, and of exposure to concentrated exhaled breath plumes limited by rapid air mixing

from environmental controls that distributed aerosols evenly. Future trials over multiple seasons,

Donors that cough, younger recipients, and environments that preserve normal exhaled breath

plumes will be required to observe transmission from naturally infected Donors under controlled

conditions and generate new insights into influenza transmission dynamics.

<u>Author Summary</u>

Human-to-human influenza virus transmission under controlled conditions could provide

insights leading to better control of epidemics and pandemics. However, a previous study using

laboratory adapted viruses produced minimal transmission. Therefore, we aimed to study

transmission from people naturally infected with circulating viruses. We recruited four cohorts of

healthy volunteer Recipients to stay in a quarantine hotel for two weeks. We could not recruit

Donors for the first two cohorts. In the last two cohorts, one Donor exposed eight Recipients in

the first and four Donors exposed three Recipients in the second. The Donors coughed

infrequently and shed less virus into the air than we had observed during previous influenza

seasons. No Recipients became infected. Possible explanations include that people infected

during mild influenza seasons or who cough very little may be minimally contagious. Our

middle-aged Recipient cohorts were older than Donors and possibly less susceptible to infection

because of additional years of vaccination and infection. Finally, environmental controls in the

hotel distributed aerosols evenly but reduced short-range exposure to concentrated clouds of

exhaled breath that may play an important role in transmission. New designs will need to address

these issues.

Introduction

In a typical year seasonal influenza is associated with hundreds of thousands of hospitalizations and tens of thousands of deaths in the US [1]. Although the 2009 pandemic influenza virus had a broadly similar severity profile to seasonal influenza [2–4], the three previous pandemics in the 20th century were associated with much greater morbidity and mortality [5]. Influenza is therefore responsible for a considerable burden of disease in the US and globally, and control of influenza is a public health priority. The effective reproductive number of seasonal influenza is estimated to be around 1.3 at the start of an influenza season, meaning that we expect an average of 1.3 secondary cases from an infected person, depending on the environment and number of people whom they come into contact with [6].

It is now well established that humans shed infectious virus into fine particle aerosols both when coughing and also when simply breathing [7]. A post-hoc analysis of household studies suggests that viral aerosols play an important role in transmission, with half of influenza transmissions in households occurring via inhalation [8]. In April 2024, the World Health Organization released a technical consultation report and defined the modes of respiratory pathogen transmission as airborne transmission/inhalation, direct deposition, and contact (direct and indirect) corresponding to a previously proposed transfer-process categorization: inhalation, spray, and touch transmission, respectively [9,10]. Despite recent emphasis on airborne transmission [9,11], the relative importance of these transmission modes remains poorly understood and an important focus of continuing research interest [12,13]. The lack of in-depth understanding of transmission modes and mechanisms impedes development, implementation, and prioritization of effective control strategies.

In 2013, a randomized controlled trial (RCT) of human challenge-transmission, Evaluating

Modes of Influenza Transmission (EMIT-1), was conducted to evaluate the relative importance

of these transmission modes [14,15]. EMIT-1, using volunteers intranasally inoculated with 10^5

50% tissue culture infectious doses ($TCID_{50}$) influenza virus as Donors, failed to meet the

expected secondary attack rate (SAR); only one serology-confirmed asymptomatic, PCR-

negative infection was identified in a Control Recipient [15]. Post-hoc analyses revealed that

Donors intranasally inoculated with influenza virus had mild symptoms and minimal shedding of

virus in exhaled breath compared with symptomatic community-acquired cases on a college

campus collected in the same year (2013) [14] as well as mildly symptomatic influenza cases

from a longitudinal cohort [16]. These findings suggested that if lack of transmission was due to

use of an egg-adapted challenge virus, a controlled human influenza virus transmission trial

(CHIVITT) with community-acquired cases as Donors could be an improved and more valid

approach to studying the dynamics of influenza transmission.

Here, we describe EMIT-2, a first attempt at a CHIVITT incorporating community-acquired

cases, and the challenges, limitations, and the insights gained regarding the dynamics of

influenza transmission.

Results

A schematic of the study design is shown in Figure 1a and the timeline of two cohorts is shown

in Figure 1b.

Study cohort and study population

By January 3, 2024, we recruited 80 potential Recipients into a study registry (S1 Fig). A total of 505 potential Donors expressed interest, with six ultimately admitted to the quarantine facility (S2 Fig). Between 2023 and 2024, we ran four quarantine cohorts: one in 2023 (23a) and three in 2024 (24a, 24b, 24c). Recipients were recruited to participate in quarantine cohorts without further selection based on antibody levels or vaccination status, due to the small number available. Recipients assigned to Intervention Recipient (IR) and Control Recipient (CR) groups using the face shield and hand hygiene intervention previously described for the EMIT-1 study using nasally inoculated Donors [15].

Despite successful enrollment of Recipients in cohorts 23a and 24a (S1 Table), we were unable to recruit Donors with natural influenza virus infection. For Cohort 23a (February 20 to March 5, 2023), the start of which was delayed due to the coronavirus disease 2019 (COVID-19) pandemic, we could not recruit Donors because the influenza season was unusually early and had ended before the quarantine commenced. For Cohort 24a (January 3 to 16, 2024), one Donor recruited based on a positive rapid influenza test reported by an outside facility was later confirmed to be infected with a seasonal coronavirus (229E), not influenza virus (S2 Table).

The later two cohorts 24b and 24c included 11 Recipients and 5 naturally infected Donors. We enrolled three IRs, five CRs and one Donor in cohort 24b (Jan 24 to Feb 6, 2024). We enrolled one IR, two CRs, and four Donors in 24c (Feb 14 to 27, 2024). All Donors reported symptom onset within the last 48 hours. However, a rapid flu test result submitted after enrollment by one of the Donors (D24c-3), on closer examination, demonstrated that they had a positive test more

than 48 hours prior to enrollment. All tested positive for influenza A virus by a molecular test

(Cepheid GeneXpert Xpress) at recruiting sites on the University of Maryland College Park

campus or on arrival at the hotel quarantine. The Donor for 24b (D24b-1) and two of the Donors

for 24c (D24c-1 and D24c-2) were infected with H3N2, while the other two Donors (D24c-3 and

D24c-4) were infected with H1N1.

For cohorts 24b and 24c, 54% of the Recipients were female and the average age was 36 (range

22-49). Two Recipients (both in Cohort 24b) received an influenza vaccine earlier in the same

influenza season before enrolling in a quarantine (Table 1). Among the five Donors, most were

female (80%) young adults, with a mean age of 21 years (Table 2).

Exposure Events and Activities

We conducted 23 exposure events involving influenza Donors, including 6 events in cohort 24b

and 17 events in cohort 24c. These events lasted between 111 and 250 minutes, totaling 82.2

cumulative influenza exposure-event hours (19.5 in 24b and 62.7 in 24c). Eleven events involved

one Donor and 12 involved two (S3 Table). During the events, volunteers engaged in

conversation-focused activities (such as icebreaker questions), interactive games (such as the

card game UNO and drawing and guessing game Telestrations), plus some physically active

periods (stretching, yoga, or dancing). A designated object was passed following a donor-

centered alternating sequence, including a marker in 19, tablet computer in 2, and microphone in

2 events (see S3 Table).

Environmental Conditions

Mechanical systems successfully maintained stable environmental conditions in the exposure

event room during exposure events through running two fan coil units and two large capacity

dehumidifiers with fans constantly on high speed. The indoor air temperature remained within

22-25°C, and relative humidity ranged between 20-45% (Figure 2). The ventilation rate was

approximately 0.25-0.5 air changes per hour. Running fan coil units and dehumidifiers at high

speed in addition to portable air cleaners without filters served to create a well-mixed

environment satisfying assumptions of the standard Wells-Riley model [17]. However, the

extensive mixing reduced the extent of Recipient exposure to concentrated plumes of exhaled

breath (a detailed computational fluid dynamic analysis will be presented elsewhere [18]).

CO_2 concentrations in the exposure event room increased rapidly during exposure events, as

occupants were the sole CO_2 source, and returned toward the background level (~420 ppm) after

the exposure event. In 24b, with 11 occupants (one Donor, eight Recipients, and two study

moderators), CO_2 levels rose from 460 to 5300 ppm, while in 24c, with 7 occupants (two Donors,

three Recipients, and two study moderators), CO_2 levels were lower, rising from 430 to 2400

ppm. Fluctuations in CO_2 correlated with variations in temperature and relative humidity. CO_2

levels in the corridor remained relatively stable near background concentrations, with minor

fluctuations caused by occasional human traffic and the opening of the exposure event room

doors.

Viral Shedding and Environmental Contamination by Donors

Exhaled Breath Aerosol Samples

Using the G-II, we collected 16 exhaled breath aerosol samples from five influenza Donors.

During each 30-minute collection period, Donors coughed and sneezed spontaneously, with

cough counts ranging from 0 to 16 (median: 0) and sneeze counts from 0 to 1 (median: 0) (S4

Table).

Among these exhaled breath aerosol samples, we detected viral RNA in seven (44%) fine (<5µm,

range: 79 – 8.9×10^3 copies per 30-minute sample) and one (6%) coarse (≥5µm, 53 copies per 30-

minute sample) aerosol sample; all from Donors with H3N2 infections. The viral RNA load in

breath aerosol samples fluctuated over time and did not follow a clear pattern across Donors

(Figures 3–4).

The only culture-positive breath fine aerosol sample contained 147 focus forming units (FFU)

per 30-minute sample (Figures 3–4). The sample came from the Donor in 24b (D24b-1; H3N2

infection) on the morning of Day 9 (February 1, 2024) their last day in quarantine, when they

coughed the most during the 30-minute exhaled breath sampling (six times) and shed their

highest breath aerosol viral RNA load (405 copies per 30-minute sample). Eight Recipients were

exposed for four hours on this day.

Mid-turbinate swabs and Saliva

We collected 18 mid-turbinate swabs (MTS) samples and 18 saliva samples from Donors. All

MTS samples contained detectable viral RNA (range: 5.32×10^4 – 3.91×10^8 genome copies/swab),

and 11 (61%) were culture positive with viral loads from 40 to 8.7×10^4 FFU/swab. Among saliva

samples, 15 (83%) contained detectable viral RNA (range: $67 - 4.37 \times 10^7$ copies/mL); however,

none were culture positive (Figures 3–4). We did not observe significant correlations between

exhaled breath aerosol viral RNA and that measured in MTS or saliva samples in this small data

set (S3 Fig).

Ambient and Personal Bioaerosol Sampling

We collected two ambient air samples and two personal breathing zone air samples during each

of 12 afternoon exposure events (one per day) when Donors were present, resulting in a total of

24 ambient and 24 personal samples.

Among the ambient samples, we detected viral RNA (75 genome copies/m^3 air) by dPCR in one

sample from cohort 24b, at sitting height (129cm) in the 1-4 µm size fraction, on January 31,

2024 – the afternoon prior to the culture positive exhaled breath sample from Donor D24b-1.

One other ambient sample, collected from cohort 24c (Donors D24c-1 & D24c-2 present;

February 19, 2024) at standing breathing level height (150cm), contained detectable viral RNA

(25 RNA copies/m^3 air) in the >4 µm size fraction (S4 Fig). None of the personal bioaerosol

samples contained detectable viral RNA by dPCR.

Surface Swab Viral Load

We collected 23 surface swabs from fomites used in exposure events with a Donor, including

two from a microphone, two from a tablet computer, and 19 from a marker pen, depending on

the activities performed (S3 Table & S4 Fig). Among these, one sample, collected from a marker

pen during the third exposure event of the Donor's second day in quarantine (24b), contained

virus detected by dPCR; it was also positive for culture (total viral load of 454 RNA copies and

20 FFU).

Symptoms Reported by Donors and Recipients

Donors reported varying levels of symptom severity across a range of individual symptoms

(Figure 5a). Throughout the quarantine period, total symptom scores fluctuated for the Donor in

24b (D24b-1), but generally declined for Donors in cohort 24c, though the rate of decline

differed among Donors (Figure 5b).

Recipients sporadically reported individual symptoms, with overall symptom severity lower than

that of Donors. Malaise was the most frequently reported symptom (Figure 6a). Total symptom

scores fluctuated over time, with most Recipients reporting more symptoms after exposure to a

Donor (Figure 6b). Three Recipients reported symptoms only on days with exposure events but

not afterward. R24b-Ctl4 in cohort 24b recorded the highest total symptom score (10) three days

after exposure to the Donor (Figure 6b).

Recipient Post-Exposure PCR and Culture

We collected a total of 89 post-exposure MTS and saliva samples from Recipients. In cohort

24b, each Recipient provided daily MTS and saliva samples on 7 days (quarantine cohort Days 8

through 14) following their first exposure event on Day 7. In cohort 24c, each provided 11

samples (Days 4 – 14) following their first exposure event on Day 3. None of the samples tested

positive by dPCR.

Serology from Donors and Recipients

Consistent with qRT-PCR test results, hemagglutination inhibition (HAI) titers for Donors

measured at admission and follow-up confirmed three H3N2 (D24b-1 from cohort 24b; D24c-1

and D24c-2 from cohort 24c) and two H1N1 (D24c-3 and D24c-4 from cohort 24c) infections

(Figures 7-8).

Among the exposed Recipients, 8 out of 11 had low HAI titers (≤10) at admission against the

vaccine strains corresponding to the Donor strains, including 6 out of 8 in cohort 24b, 2 out of 3

in cohort 24c (Figures 7-8), and one of the two vaccinated for the current season. However, none

of the Recipients showed a four-fold increase in HAI titers against the vaccine strains from

admission to follow-up, except for one Recipient in cohort 24b (R24b-Ctl3), who responded to

all vaccine strains and reported having received an influenza vaccine two days after discharge

from quarantine.

The enzyme-linked immunosorbent assay (ELISA) results were generally consistent with the

HAI titer findings, as none of the Recipients showed a four-fold increase in area under the curve

(AUC) values against vaccine strains HAs corresponding to the Donor infections, including the

Recipient who received an influenza vaccine after quarantine (S5 Fig & S6 Fig). However,

ELISA results indicated higher AUC values in Recipients than in Donors at baseline. In cohort

24b, all eight Recipients had higher AUC values at admission compared to the Donor. Similarly,

in cohort 24c, one of three Recipients had a much higher AUC value than their Donor

counterparts at admission.

Discussion

We developed a novel framework for investigating human influenza virus transmission using

Donors with community-acquired infections under controlled conditions. However, despite

enrolling five naturally infected Donors within 48 hours of reported symptom onset, promoting

prolonged close contact under low ventilation conditions with 11 Recipients, many with low HAI

titers, no secondary infections were observed. Three possible explanations related to Donor

source strength, Recipient susceptibility, and rapid air mixing may provide insight into influenza

transmission dynamics and guide future study designs.

Donors in our present study, EMIT-2, shed detectable viral RNA somewhat more frequently, but

not significantly more frequently than had been observed in EMIT-1 Donors infected with an

egg-adapted laboratory virus: 44% (7/16) versus 22% (14/64) of fine and 6% (1/16) versus 9%

(6/64) of coarse aerosol samples in EMIT-2 and EMIT-1, respectively [16]. EMIT-2 Donor

aerosol shedding frequency was on the low end of previous observations of natural influenza

infections, which ranged from 38% to 86% for fine aerosols and 29% to 86% for coarse aerosols

[7,16,19]. The rate of viral RNA shedding into fine aerosols (≤5 μm) by EMIT-2 Donors was

also similar to rate from the small fraction of experimentally infected Donors in EMIT-1 who

had detectable aerosol shedding (range 1.6×10^2 to 1.8×10^4 copies per hour in EMIT-2 v. 2.6×10^2

to 1.6×10^5 copies per hour in EMIT-1) [15,20].

Looking specifically at symptomatic, ILI cases on our campus infected with H3N2 from the

2012-13 and 2018-19 seasons, we previously noted that cases recruited during a milder influenza

seasons may, on average, shed lower quantities of viral RNA into exhaled breath [16]. We also

noted that cases recruited by intensive case finding had milder symptoms and shed less

frequently into aerosols. The results here are consistent with these earlier observations in that

2023-24 was a relatively mild season, most Donors were recruited by offering free tests at a

kiosk on campus, and Donor D24b-1, with the strongest evidence for potential infectiousness,

was the only donor recruited from the University Health Center.

Based on evidence for transmission to one Recipient in EMIT-1, Bueno de Mesquita et al.

estimated a lower bound for an infectious quantum (i.e., the ID 63% via inhalation [21]) of

approximately 1.4×10^5 RNA copies [20]. Recent aerosol inoculation experiments suggest that,

with an egg-adapted laboratory strain, the infectious dose in approximately 10^4 $TCID_{50}$. During

EMIT-2, using an average minute-ventilation rate of 16 L/min based on Recipient activities and

the two positive NIOSH bioaerosol samples, we estimate that on January 31, Recipients in

Cohort 24b were exposed to approximately 750 RNA copies each. On February 19, each

Recipient in Cohort 24c received an exposure of approximately 290 RNA copies (S4 Text).

These exposures fell well below the infectious dose estimated from EMIT-1 and recent aerosol

inoculation experiments. Therefore, low overall contagiousness of our Donors may be a key

reason why no transmission was observed in this study.

This occurred despite two Donors (D24b-1 and D24c-2) having low Ct values from mid-

turbinate swabs tested by Cepheid at admission to the hotel quarantine: 12.1 and 16.1 for D24b-1,

who was recruited from the University Health Center, and 12.2 and 14.6 for D24c-2. We

previously reported that viral load in the nose did not reliably predict exhaled virus

concentrations [7]. Donor D24b-1 did not report cough and only coughed during the last of three

exhaled breath collections – when we detected infectious virus in their breath. Similarly, Donor

D24C-2 only coughed during the last exhaled breath collection. Cough observed during sample

collection is a major predictor of viral shedding into aerosols. For future controlled studies of

transmission from natural infections, it may be necessary to focus on recruiting Donors who

cough.

In addition, we previously observed substantial heterogeneity in viral aerosol shedding in studies

of community-acquired influenza and SARS-CoV-2 infections [7,16,22]. Recent human

challenge studies have reported similar variability. For example, in a SARS☐CoV☐2 challenge,

two participants accounted for 86% of airborne virus released, despite many being infected [23].

Similarly, a recent influenza challenge study found wide variation in the aerosol emissions of

infected donors [24]. These consistent findings across both naturally acquired and controlled

infections underscore the importance of inter-individual variability in aerosol shedding. Such

heterogeneity likely contributes to the overdispersion of transmission seen in real-world

outbreaks and may help explain the generally low aerosol shedding observed in our Donors.

The absence of transmission may also be attributable to Recipient pre-existing immunity.

Although most of the Recipients had low HAI titers (≤10) against the vaccine strains

corresponding to Donor viruses, their ELISA AUC values against these strains were higher at

baseline those of Donors, suggesting potential for some degree of pre-existing immunity from

prior infections or vaccinations. The EMIT-1 challenge study began with a registry of 496

volunteers with HAI titers ≤10 against the challenge virus, who reported not having had a

seasonal influenza vaccine in the last 3 years [15]. In contrast, our current study had a much

smaller registry pool (80 volunteers). Over one-fourth of Recipients whom we later exposed to

an influenza Donor had baseline HAI titers >10 and nearly one-third of registry members

received an influenza vaccine during the same influenza season as the quarantine, including two

who were later exposed to an influenza Donor. Given that our Recipients were middle-aged

adults, they would have had greater cumulative exposure to influenza virus infections and

vaccinations than our Donors, further contributing to broader immunity. Older adults are more

likely than children to develop enhanced pre-existing cross-reactive antibodies due to prior

infections and vaccinations [25], and middle-aged adults are less likely than young adults to

show evidence of infection in large population studies [26]. Therefore, future transmission trials

should focus on recruiting younger adults into the pool of volunteer recipients.

Finally, temperature and humidity during exposure events were within the range likely to

promote transmission and therefore do not explain the lack of observed transmission in this study.

Laboratory and animal studies reviewed by Arundel et al. [27] suggest that influenza virus

survival and transmission are enhanced at low relative humidity (<40%) and may increase again

at high humidity (>70%), with a mid-range of ~40–70% minimizing combined infectivity and

survival. According to standards from the American Society of Heating, Refrigerating and Air-

Conditioning Engineers (ASHRAE), thermal comfort for most individuals lies between 67-82 °F

(19.4–27.8°C)[28]. In our study, temperatures were maintained at 22–25°C and relative humidity

ranged from 20% to 45%, a range that supports participant comfort while enabling influenza

survival and transmission.

Although the relationship between ventilation and airborne transmission is complex, low air

change rates have been linked to increased risk in healthcare and public settings [29]. Menzies et

al. [30], for example, observed higher tuberculosis infection risk in hospital rooms ventilated at

<2 air changes per hour (ACH). While no universal minimum threshold has been validated, we

maintained ventilation at ~0.25–0.5 ACH to support transmission. To achieve temperature and

relative humidity control in the hotel room used for exposure events, in the presence of low

ventilation and seven or more occupants, we ran the room's two fan coil units at maximum speed

and added two large capacity portable dehumidifiers. Operation of these fans produced high rates

of air mixing.

Controlled test chamber and modeling studies show that high rates of air mixing reduce short-

range aerosol exposure [31,32] by rapidly breaking up concentrated plumes of exhaled breath.

Exposure to concentrated plumes may be a critical factor in transmission via aerosol inhalation,

especially from hosts with low to moderate viral aerosol shedding rates. Given the low viral

aerosol shedding rates of our Donors, rapid air mixing with reduced short-range aerosol exposure

may have contributed to lack of transmission in this study. Future studies using an indoor climate

facility designed for indoor air quality and climate studies and capable of controlling temperature

and humidity with controlled, minimal air movement and ventilation could avoid this problem.

Together, the three possible explanations for lack of transmission in this study (source strength,

susceptibility, and air mixing) may provide insight into the transmission of seasonal influenza.

For seasonal influenza, previous studies suggest that 4 to 7 out of 10 cases shed some virus into

aerosols. But the geometric mean shedding rate per hour observed was at most one tenth of the

infectious dose estimated from EMIT-1 for a selected population with minimal immunity.

Although the average infectious dose for a population with some cross-reactive immunity may

be higher, susceptibility to circulating human virus without laboratory adaptation is likely lower.

Therefore, an infectious dose associated with exhaled breath aerosols in the rage of 10^4 to 10^5

viral RNA copies seems reasonable. Shedding rates are lognormally distributed and the upper tail

extended to 10^7 to 10^8 RNA copies/hour, suggesting that some cases rare cases may shed as

many as 100 to 1000 infectious quanta per hour [7]. However, reported geometric mean aerosol

shedding rates suggest that only more symptomatic cases with cough would be expected to shed

one or more infectious doses per hour and that mild cases would rarely be contagious [16]. This

evidence for influenza virus supershedding suggests that while the average symptomatic case

may be able to transmit to someone through prolonged exposure to concentrated breath plumes, a

few cases may be able to transmit relatively rapidly with less intense and prolonged exposures.

An additional implication may be that prolonged face-to-face contact and a moderate degree of

superspreading combine to generate seasonal influenza epidemics.

These considerations suggest that future controlled experiments aiming to observe transmission

from naturally infected cases focus on recruiting Donors with cough and young adult volunteers

with low rates of prior immunity as Recipients. It also points to advantages of a controlled

environment with limited air mixing that allows exhaled plumes to linger, such as certain

displacement ventilation arrangements [33].

The unpredictable timing and duration of influenza seasons pose a challenge for conducting a

CHIVITT using Donors with community-acquired infection. The inability to recruit an influenza

virus-positive Donor in 2023, due to an early and short influenza season, highlighted the need to

prepare for potential quarantines from November through early March to capture both early and

late influenza seasons, as we did for the 2023-24 influenza season. The resulting prolonged hotel

rental including months without influenza activity, added considerable expense. New more

flexible designs that can respond to timing of seasonal influenza activity without tying up

resources for prolonged periods are needed. An approach that can leverage existing campus-

based indoor environment research infrastructure and also study other respiratory viruses when

influenza is not actively circulating could be cost effective. Another limitation was that Control

Recipients may have reduced behaviors such as touching their face or eyes, which are relevant to

touch-contact transmission. To better ensure potential for occurrence of touch-contact

transmission additional behavioral requirements, such as instructing Control Recipients to touch

their face at regular intervals as previously described for rhinovirus studies [34], could be

incorporated and create a clear contrast with the hand hygiene intervention. Finally, we note that

mucosal immunity, both innate and acquired, play an important role in susceptibility to initial

infection and were not examined in this study.

Conclusions

Lack of transmission from mild influenza cases, who rarely coughed, to healthy middle-aged

volunteers in a room with rapid air mixing may provide some insights into influenza

transmission dynamics. Transmission from healthy young adults may be dominated by the

symptomatic cases with cough. Consistent with population data, middle-aged adults may be

relatively immune to circulating influenza viruses. Finally, concentrated breath plumes may play

an important role in transmission of seasonal influenza viruses. Future studies addressing these

three factors are needed to advance our understanding of the role of inhalation exposure in

transmission of seasonal influenza viruses.

Materials and Methods

Overview of Study Design

In this CHIVITT our study population consisted of two groups of volunteers – healthy volunteer

Recipients without evidence of respiratory infection on a multiplex molecular test, and Donors

with recent-onset community-acquired influenza virus infection. Recipients consented to stay in

a quarantine hotel for two weeks, while Donors agreed to stay for two to five days. Donors and

Recipients interacted during exposure events in an exposure-event room sealed to provide low

ventilation. The Recipients were randomly assigned to intervention Recipient (IR) or control

Recipient (CR) groups. IRs wore a face shield to interrupt direct deposition transmission and

sanitized their hands every 15 minutes to interrupt direct and indirect contact (touch)

transmission; IR and CR groups in each exposure event received similar risk from inhalation of

infectious respiratory particle aerosols. CRs did not wear face shield or sanitize their hands

during the exposure event; they would have been exposed to all modes of transmission (Figure 1).

Study Setting

This study took place in a dedicated, isolated floor of a hotel in Baltimore, Maryland, USA that

had been used as a quarantine hotel for COVID-19. We equipped 18 rooms for individually

housing up to 16 Recipients and 2 Donors.

Volunteer Recruitment

We recruited healthy volunteers aged 18 through 49 to enroll in a Recipient registry. Registry

members who remained eligible, available, and willing to commit to a two-week stay in the hotel

quarantine environment were admitted as Recipients at the start of each cohort study.

Concurrently, community members aged 18 through 59 with PCR-confirmed influenza virus

infection and symptom onset within 48 hours were recruited and admitted to the quarantine

facility as Donors. Eligibility criteria of Donors and Recipients are detailed in the Supporting

Information (S3 Text).

Randomization, Concealment, and Blinding

Recipients were randomly assigned to either the intervention group, receiving a hand hygiene

and face shield intervention (HH+FS) as an IR, or the control group, receiving no intervention as

a CR. We used randomization tables generated by a statistician, which were uploaded into the

randomization module in REDCap (Research Electronic Data Capture) [35] to assign Recipients.

REDCap was also used for data collection and management for this study.

Recipients and staff were unaware of the intervention assignment at enrollment; however,

concealment during the study was not possible due to the nature of the intervention. All research

nurses who collected biological samples and laboratory technicians who conducted PCR and

serologic assays were blinded to the Recipients' assignments.

Exposure Event

During each exposure event, Donors and Recipients participated in structured activities intended

to elicit sustained verbal interaction and standardized touch contact with a designated object

passed from Donors to Recipients. Activities ranged from physically demanding exercises such

as yoga and dancing to more sedentary activities like solving puzzles and watching movies. Each

exposure event included activities that required participants to handle a shared object (marker,

tablet computer, or microphone), during which a donor-centered alternating sequence was used:

one Donor handed the object to a Recipient, the object was returned to a Donor, and the Donor

then passed it to the next Recipient continuing until all Recipients had participated before

beginning a new round. Two staff members were present at the exposure event room to observe,

document, and moderate activities.

Symptom Monitoring

Both Donors and Recipients assessed their symptom twice daily by answering a survey,

Modified Jackson Score, in their mobile device. They self-reported on a scale of 0 to 3 (0 = "no

symptom", 1 = "Just noticeable", 2 = "Bothersome from time to time, but doesn't prevent me

from doing activities", and 3 = "Bothersome most or all the time, and prevents me from doing

activities") for the following symptoms: running nose, stuffy nose, sneezing, sore throat, earache,

malaise (tiredness, fatigue), headache, muscle and/or joint ache, chills, feverish, chest tightness,

shortness of breath, and cough.

Biological Sample Collection

Mid-turbinate swabs (MTS) and saliva samples were collected daily from both Donors and

Recipients. Blood samples were collected from both groups at three key time points: admission

(at the start of the quarantine cohort, before any exposure event), discharge (at the end of the

quarantine cohort), and a 28-day follow-up.

Exhaled breath sampling

Donors provided exhaled breath samples using a Gesundheit-II (G-II) exhaled breath aerosol

sampler [36] on admission to the quarantine hotel and each morning thereafter. G-II samples

were collected for a 30-minute period with the volunteers breathing normally, while shouting and

singing loudly three times at 5, 15, 25 minutes, as previous described [22]. The G-II samples

were categorized into two aerosol size fractions, including fine (≤5 µm in diameter) and coarse

(>5 µm in diameter) aerosols.

Ambient and personal bioaerosol sampling

To collect ambient air samples during exposure events, we used a ceiling track system to position

bioaerosol sampling devices developed by the National Institute for Occupational Safety and

Health (NIOSH BC-251) [37] at sitting and standing breathing level heights (129cm and 150cm)

in the designated exposure event room (Figure 1). To measure personal, breathing zone influenza

virus aerosol exposure, we mounted NIOSH BC-251 samplers to the front strap of small

backpacks containing a compact SKC AirChek TOUCH pump (Figure 1a). Each sample pump

was calibrated to 3.5 L/min and all samples were collected for 4 hours (840 liters). We sampled

one 4-hour exposure event per day for both ambient and personal influenza bioaerosols. For each

sampled exposure event, we randomly selected one CR and one IR to wear a sampling kit. We

extracted bioaerosol samples in 1 mL of extraction buffer and quantified viral RNA. To

calculate RNA concentration per cubic meter of air, we divided the viral RNA copy number in

each 1-mL sample by the total sampled volume ($0.84\,m^3$), yielding RNA copies per m^3 of air.

Surface swab sampling

During each exposure event, a selected object (marker, microphone, or a tablet computer, 10.2-

inch iPad) used in planned activities was passed between Donors and Recipients. At the end of

the exposure event, the object was swabbed for surface sampling before decontamination.

Environmental Interventions and Infection Prevention

The interactions between Donors and Recipients took place in a specially prepared exposure-

event room in the quarantine hotel. To control temperature and humidity during high room

occupancy, we operated the room's two built-in recirculating fan coil units equipped with

MERV-8 filters on continuous high fan mode and installed two dehumidifiers. We also sealed

major uncontrolled air pathways, including windows, doors and a leak in the fan coil units, prior

to the quarantine cohorts to establish low ventilation, poor air hygiene conditions. To ensure that

aerosols were distributed evenly and that mixing conditions did not change for exposure events

when we used portable air filters to create high air hygiene conditions in future experiments, we

ran the portable filter units without filters at the planned low-moderate fan speed.

We continuously monitored CO_2 concentration, indoor air temperature, and relative humidity in

the exposure event room during each exposure event using eight uniformly distributed Aranet4

pro sensors, positioned on the walls at 1.0 and 1.5 meters above the floor, and two sensors

suspended from the ceiling at a height of 2.1 meters. Additionally, we installed two Aranet4 pro

sensors in the hallway near the exposure event room doors at a height of 1.5 meters. Using CO_2

concentration results, we calculated the ventilation rate of the room based on the concentration

decay method [38].

To mitigate the risk of airborne inhalation/transmission outside of the exposure event room, we

converted the entire floor into a quarantine facility through implementing an effective air

cleaning strategy, incorporating 222-nm GUV fixtures and portable HEPA air cleaners in the

hallways, and in-room portable HEPA air cleaners in the rooms other than the exposure event

room (details described previously [39]). We also covered all the bathroom exhausts on the floor

with MERV-16 filters and installed a portable HEPA/carbon filter unit in the bathroom of the

exposure event room. Both Donors and Recipients stayed in assigned individual rooms equipped

with in-room portable HEPA air cleaner and air curtains over the doorways when not

participating in an exposure event. The room used for blood and swab collection was equipped

with a portable HEPA filter, 222-nm GUV, and a local HEPA filtered exhaust for the

participant's breathing zone. Donors and Recipients wore duckbill N95 respirators when outside

of their rooms except during exposure events.

Laboratory Analysis

BioFire and Cepheid GeneXpert Xpress Tests

Recipient admission and day 2 samples were submitted to the University of Maryland Hospital

clinical laboratory for BioFire respiratory panel testing. Donor admission and daily Recipient

samples, starting after exposure to Donors, were tested at the hotel quarantine using a Cepheid

GeneXpert Xpress Cov-2/Flu/RSV plus 4-plex test panel.

Digital PCR (dPCR) and Fluorescent Focus Assay

Total nucleic acids were extracted from G-II, mid-turbinate swabs, saliva, surface swabs, and

ambient air samples for viral RNA detection. Influenza A virus RNA was quantified using

recently updated primers and probes targeting the matrix (M) gene segment of influenza A

viruses [40] and the QIAcuity One dPCR System (Qiagen). To assess viral infectivity, we

measured focus-forming units (FFU) in G-II fine aerosol samples, mid-turbinate swabs, and

surface swabs using humanized Madin-Darby canine kidney cells [41], adapting a previously

described method [7]. Further details on sample processing and nucleic acid extraction are

provided in Supporting Information (S4 Text).

Serology

Blood samples were analyzed at the Icahn School of Medicine at Mount Sinai, NY, USA. Serum

samples from all Recipients and Donors were tested in triplicate to assess hemagglutination

inhibition (HAI) antibody titers against influenza virus strains included in the 2023–2024

influenza vaccine: A/Victoria/4897/22 (H1N1), A/Darwin/6/21 (H3N2), and

B/Austria/1359417/21. An enzyme-linked immunosorbent assay (ELISA) was used to assess the

area under the curve (AUC) for binding antibody responses against A/Victoria/4897/22 H1 and

A/Darwin/6/21 H3. Further details on assay procedures are provided in in Supporting

Information (S4 Text).

Data Analysis

The primary outcome of this study was SAR of influenza virus infections among the Recipients,

including virological confirmation, symptomatic infections, or serological evidence of an

infection.

Descriptive analyses were conducted to summarize the characteristics of both Donors and

Recipients. Violin plots and Loess-smoothed curves were used to visualize viral loads in Donor

samples and their temporal trends. Heatmaps and line plots illustrated maximum individual

symptom score distributions and changes in total symptom scores over time for both Donors and

Recipients. To assess immune responses, HAI titers against vaccine virus strains were plotted to

show changes over time. Line plots were also used to depict environmental factors, including

indoor temperature, relative humidity, and CO_2 concentration. Statistical analyses were done in

R and RStudio.

Ethical Considerations

The study was registered at ClinicalTrials.gov (NCT05666245) and approved by the Intuitional

Review Board of the University of Maryland, Baltimore. All participants provided written

informed consent before enrollment, with assurances of confidentiality and the right to withdraw

at any time without consequence.

<u>Acknowledgments</u>

The authors thank the volunteer participants, hotel staff, and all of the research faculty, fellows,

and student research assistants of the Public Health AeroBiology Lab, the Center for

Sustainability in the Built Environment (City@UMD), the Maryland MEMS & Microfluidics

Lab, and Duncan Lab at the University of Maryland, College Park, as well as the clinical staff

and research nurses at the University of Maryland, Baltimore, for their contributions to volunteer

recruitment, study coordination, sample collection, and laboratory processing (A complete list of

contributors can be found in S2 Text. Acknowledged Contributors). We also thank Bill Lindsley

for providing the NIOSH BC-251 bioaerosol samplers used in this project.

This study was supported by NIAID Cooperative agreement U19 grant (5U19AI162130), by the

University of Maryland Baltimore, Institute for Clinical & Translational Research (ICTR) and

the University of Maryland Strategic Partnership: *MPowering the State* (MPower), and by gifts

from The Flu Lab and Balvi Filanthropic Fund.

Author Contributions

Conceptualization: Donald K. Milton, Jelena Srebric, Florian Krammer, Benjamin J. Cowling,

Aubree Gordon, Wilbur Chen

Data Curation: Filbert Hong, Jianyu Lai, Hamed Sobhani

Formal Analysis: Jianyu Lai, Hamed Sobhani

Funding Acquisition: Donald K. Milton, Jelena Srebric, Don L.DeVoe, Wilbur H. Chen, Justin R.

Ortiz, Shuo Chen, Florian Krammer, Benjamin J. Cowling, Aubree Gordon, Yoshihiro Kawaoka,

Gabriele Neumann, Gregory S. Lewis, Arantza Eiguren-Fernandez

Investigation: Jianyu Lai, Hamed Sobhani, Kristen K. Coleman, S.-H. Sheldon Tai, Filbert Hong,

Isabel Sierra Maldonado, Yi Esparza, Kathleen M. McPhaul, Shengwei Zhu, Juan Manuel

Carreno, Temima Yellin, Jennifer German, Wilbur H. Chen

Project Administration: Filbert Hong, Isabel Sierra Maldonado, Yi Esparza

Software: Filbert Hong

Supervision: Donald K. Milton, Jelena Srebric, Wilbur H. Chen, Florian Krammer

Validation: Filbert Hong, Jianyu Lai, Hamed Sobhani, Temima Yellin, Shengwei Zhu

Visualization: Jianyu Lai, Hamed Sobhani, Isabel Sierra Maldonado

Writing – Original Draft Preparation: Jianyu Lai, Hamed Sobhani, Kristen K. Coleman, S.-H.

Sheldon Tai, Temima Yellin, Donald K. Milton

Writing – Review & Editing: Jianyu Lai, Hamed Sobhani, Kristen K. Coleman, S.-H. Sheldon

Tai, Filbert Hong, Isabel Sierra Maldonado, Yi Esparza, Kathleen M. McPhaul, Shengwei Zhu,

Jelena Srebric, Don L. DeVoe, Justin R. Ortiz, Wilbur H. Chen, Shuo Chen, Temima Yellin,

Juan Manuel Carreno, Florian Krammer, Benjamin J. Cowling, Aubree Gordon, and Donald K.

Milton

References

1.   Rolfes MA, Foppa IM, Garg S, et al. Annual estimates of the burden of seasonal influenza
in the United States: A tool for strengthening influenza surveillance and preparedness.
Influenza Other Respir Viruses **2018**; 12:132–137.

2.   Wong JY, Kelly H, Ip DKM, Wu JT, Leung GM, Cowling BJ. Case fatality risk of
influenza A (H1N1pdm09): a systematic review. Epidemiology **2013**; 24:830–841.

3.   Wong JY, Kelly H, Cheung C-MM, et al. Hospitalization Fatality Risk of Influenza
A(H1N1)pdm09: A Systematic Review and Meta-Analysis. Am J Epidemiol **2015**;
182:294–301.

4.   Wu JT, Ma ESK, Lee CK, et al. The infection attack rate and severity of 2009 pandemic
H1N1 influenza in Hong Kong. Clin Infect Dis **2010**; 51:1184–1191.

5.   Horimoto T, Kawaoka Y. Influenza: lessons from past pandemics, warnings from current
671   incidents. Nat Rev Microbiol **2005**; 3:591–600.

672   6.   Biggerstaff M, Cauchemez S, Reed C, Gambhir M, Finelli L. Estimates of the reproduction
673   number for seasonal, pandemic, and zoonotic influenza: a systematic review of the
674   literature. BMC Infect Dis **2014**; 14:480.

675   7.   Yan J, Grantham M, Pantelic J, et al. Infectious virus in exhaled breath of symptomatic
676   seasonal influenza cases from a college community. Proc Natl Acad Sci USA **2018**;
677   115:1081–1086.

678   8.   Benjamin J. Cowling, Dennis K. M. Ip, Vicky J. Fang, et al. Aerosol transmission is an
679   important mode of influenza A virus spread. Nature Communications **2013**; 4:1935–1935.

680   9.   World Health Organization. Global technical consultation report on proposed terminology
681   for pathogens that transmit through the air. 2024. Available at:
682   https://www.who.int/publications/m/item/global-technical-consultation-report-on-proposed-
683   terminology-for-pathogens-that-transmit-through-the-air.

684   10.   Li Y. Basic routes of transmission of respiratory pathogens-A new proposal for
685   transmission categorization based on respiratory spray, inhalation, and touch. Indoor Air
686   **2021**; 31:3–6.

687   11.   Tellier R, Li Y, Cowling BJ, Tang JW. Recognition of aerosol transmission of infectious
688   agents: a commentary. BMC Infectious Diseases **2019**; 19:101.

689   12.   Erbelding EJ, Post DJ, Stemmy EJ, et al. A Universal Influenza Vaccine: The Strategic Plan
690   for the National Institute of Allergy and Infectious Diseases. J Infect Dis **2018**; 218:347–
691   354.

692   13.   RFA-AI-25-035: Influenza Transmission Research Consortium (P01 Clinical Trial
693   Optional). Available at: https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-25-035.html.
694   Accessed 2 September 2025.

695   14.   Bueno de Mesquita PJ, Nguyen-Van-Tam J, Killingley B, et al. Influenza A (H3) illness
696   and viral aerosol shedding from symptomatic naturally infected and experimentally infected
697   cases. Influenza Other Respir Viruses **2021**; 15:154–163.

698   15.   Nguyen-Van-Tam JS, Killingley B, Enstone J, et al. Minimal transmission in an influenza
699   A (H3N2) human challenge-transmission model within a controlled exposure environment.
700   PLoS Pathog **2020**; 16:e1008704.

701   16.   Lai J, Bueno de Mesquita PJ, Hong F, Ma T, Cowling BJ, Milton DK. Comparison of Viral
702   Aerosol Shedding by Mild and Moderately Symptomatic Community-Acquired and Nasally
703   Inoculated Influenza A(H3) Infection. Influenza Other Respir Viruses **2025**; 19:e70129.

704   17.   Riley EC, Murphy G, Riley RL. Airborne spread of measles in a suburban elementary
705   school. Am J Epidemiol **1978**; 107:421–432.

706   18.   Sobhani H, Vanama G, Coleman K, et al. Numerical Exposure Assessment in a Densely
707   Populated, Well-mixed Room with Low Ventilation (In Preparation). 2025;

708   19.   Chow VTK, Tay DJW, Chen MIC, Tang JW, Milton DK, Tham KW. Influenza A and B
709   Viruses in Fine Aerosols of Exhaled Breath Samples from Patients in Tropical Singapore.
710   Viruses **2023**; 15:2033.

711   20.   Bueno de Mesquita PJ, Noakes CJ, Milton DK. Quantitative aerobiologic analysis of an
712   influenza human challenge-transmission trial. Indoor Air **2020**; 30:1189–1198.

713   21.   Wells WF. Airborne Contagion and Air Hygiene: An Ecological Study of Droplet Infection.
714   Cambridge, MA: Harvard University Press, 1955.

715   22.   Lai J, Coleman KK, Tai SHS, et al. Exhaled Breath Aerosol Shedding of Highly
716   Transmissible Versus Prior Severe Acute Respiratory Syndrome Coronavirus 2 Variants.
717   Clin Infect Dis **2023**; 76:786–794.

718   23.   Zhou J, Singanayagam A, Goonawardane N, et al. Viral emissions into the air and
719   environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human
720   study. The Lancet Microbe **2023**; 0. Available at:
721   https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(23)00101-
722   5/fulltext#%20. Accessed 11 June 2023.

723   24.   Vargas-Maldonado N, Shetty N, Ferreri LM, et al. Controlled human influenza infection
724   reveals heterogeneous expulsion of infectious virus into air. 2025; :2025.11.03.25339190.
725   Available at: https://www.medrxiv.org/content/10.1101/2025.11.03.25339190v1. Accessed
726   17 November 2025.

727   25.   Lopez CE, Legge KL. Influenza A Virus Vaccination: Immunity, Protection, and Recent
728   Advances Toward A Universal Vaccine. Vaccines (Basel) **2020**; 8:434.

729   26.   Brugger J, Althaus CL. Transmission of and susceptibility to seasonal influenza in
730   Switzerland from 2003 to 2015. Epidemics **2020**; 30:100373.

731   27.   Arundel AV, Sterling EM, Biggin JH, Sterling TD. Indirect health effects of relative
732   humidity in indoor environments. Environ Health Perspect **1986**; 65:351–361.

733   28.   ASHRAE. Technical FAQ ID 92: What are the recommended temperature and humidity
734   levels for indoor environments? 2014; Available at:
735   https://www.ashrae.org/File%20Library/Technical%20Resources/Technical%20FAQs/TC-
736   02.01-FAQ-92.pdf.

737   29.   ASHE: Mgt Mono - Literature Review: Room Ventilation and Airborne Disease
738   Transmission | ASHE. Available at:
739   https://www.ashe.org/management_monographs/mg2013memarzadeh. Accessed 19
740   November 2025.

30.   Menzies D, Fanning A, Yuan L, FitzGerald JM. Hospital ventilation and risk for
tuberculous infection in canadian health care workers. Canadian Collaborative Group in
Nosocomial Transmission of TB. Ann Intern Med **2000**; 133:779–789.

31.   Li W, Chong A, Hasama T, et al. Effects of ceiling fans on airborne transmission in an air-
conditioned space. Building and Environment **2021**; 198:107887.

32.   Li J, Zuraimi S, Schiavon S. Should we use ceiling fans indoors to reduce the risk of
transmission of infectious aerosols? Indoor Environments **2024**; 1:100039.

33.   Bjørn E, Nielsen PV. Dispersal of exhaled air and personal exposure in displacement
ventilated roomsAbstract. Indoor Air **2002**; 12:147–164.

34.   Dick EC, Jennings LC, Mink KA, Wartgow CD, Inhorn SL. Aerosol transmission of
rhinovirus colds. J Infect Dis **1987**; 156:442–448.

35.   Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
capture (REDCap)—A metadata-driven methodology and workflow process for providing
translational research informatics support. Journal of Biomedical Informatics **2009**; 42:377–
381.

36.   McDevitt JJ, Koutrakis P, Ferguson ST, et al. Development and Performance Evaluation of
an Exhaled-Breath Bioaerosol Collector for Influenza Virus. Aerosol Sci Technol **2013**;
47:444–451.

37.   Lindsley WG, Schmechel D, Chen BT. A two-stage cyclone using microcentrifuge tubes
for personal bioaerosol sampling. J Environ Monit **2006**; 8:1136–1142.

38.   Batterman S. Review and Extension of CO2-Based Methods to Determine Ventilation
Rates with Application to School Classrooms. Int J Environ Res Public Health **2017**;
14:145.

39.   Sobhani H, Zhu S, Srebric J. Hotels as Quarantine Facilities with Airborne Virus Controls.
Building and Environment **2025**; :112765.

40.   Shu B, Kirby MK, Davis WG, et al. Multiplex Real-Time Reverse Transcription PCR for
Influenza A Virus, Influenza B Virus, and Severe Acute Respiratory Syndrome
Coronavirus 2. Emerg Infect Dis **2021**; 27:1821–1830.

41.   Takada K, Kawakami C, Fan S, et al. A humanized MDCK cell line for the efficient
isolation and propagation of human influenza viruses. Nat Microbiol **2019**;

Supporting Information

S1 Text. EMIT-2 Study Team

S2 Text. Acknowledged Contributors

S3 Text. Eligibility Criteria

S4 Text. Supplementary Methods

S1 Table. All Recipients demographics

S2 Table. All Donors demographics

S3 Table. Exposure events & activities

S4 Table. Summary of Donors cough and sneeze counts during 30-minute breath sample sampling

S1 Fig. Consort diagram for Recipients
Three Recipients from Cohort 23a re-enrolled in 2024. Two initially joined Cohort 24a, but one was discharged before the study began due to a respiratory infection other than influenza and later re-enrolled in Cohort 24c. Another Recipient from Cohort 23a also joined Cohort 24c. As a result, the total number of distinct individuals who entered quarantine was 27, rather than the summed total (31) from each individual cohort.
Note: Influenza Donors were only enrolled in cohorts 24b and 24c; no influenza Donors were enrolled in 23a or 24a.

S2 Fig. Consort diagram for Donors
a. "Phone call received" includes inquiries from social media, flyers, television, and other advertisements.
b. Many individuals were ineligible due to lack of influenza infection or were unavailable to commit to the quarantine period.
c. Ineligibility among screened individuals included symptom onset >48 hours or underlying medical conditions that did not meet eligibility criteria (S3 Text).
d. The Donor enrolled in cohort 24a, recruited from among the phone calls received, tested positive for a seasonal coronavirus (229E); no Donors were recruited for cohort 23a.

S3 Fig. Lack of correlation of Donor exhaled breath aerosol viral RNA with viral RNA in either Donor MTS or saliva samples.
Scatterplots show pairwise correlations of viral RNA concentrations measured from exhaled breath aerosol samples (left column: particles <5 µm; right column: particles ≥5 µm) against matched MTS (top row) and saliva (bottom row) samples collected from the same Donors on the same days. Each point represents one Donor–day measurement, with colors and shapes denoting individual Donors. Solid points represent samples from Donors with H3N2 infections, while hollow points represent samples from Donors with H1N1 infections. Black lines indicate linear regression fits with 95% confidence intervals. Pearson correlation coefficients (r) and sample sizes (n) are shown within each plot.

S4 Fig. Viral load in ambient bioaerosol and surface swab samples

(a) RNA copies from ambient bioaerosol samples collected using NIOSH BC-251 bioaerosol
sampling devices, stratified by size fraction (>4 μm, 1–4 μm, and <1 μm).
(b) RNA copies (left y-axis) and infectious viral load (FFU, right y-axis) from surface swabs
collected from marker pens, microphones, and tablets. Each point represents one sample. Only
one surface sample, collected from a marker pen, contained virus detected by dPCR; it was also
positive by viral culture.
827

S5 Fig. ELISA Area Under the Curve (AUC) over time for Donors and Recipients in
Cohort 24b
ELISA AUC values are shown for Donors (solid lines, filled circles) and Recipients (dot-dashed
lines, open circles) at four time points: T0 (Recipient screening), T1 (Admission), T2
(Discharge), and T3 (Follow-up). Virus targets are color-coded: A/Victoria/4897/22 (H1N1,
blue) and A/Darwin/6/21 (H3N2, green). Each facet represents an individual study participant.
834

S6 Fig. ELISA Area Under the Curve (AUC) over time for Donors and Recipients in
Cohort 24c
ELISA AUC values are shown for Donors (solid lines, filled circles) and Recipients (dot-dashed
lines, open circles) at four time points: T0 (Recipient screening), T1 (Admission), T2
(Discharge), and T3 (Follow-up). Virus targets are color-coded: A/Victoria/4897/22 (H1N1, blue)
and A/Darwin/6/21 (H3N2, green). Each facet represents an individual study participant.

Tables

Table 1. Recipients Demographics for Cohorts 24b & 24c

	Cohort 24b		Cohort 24c		All
	CTL	INT	CTL	INT	
Number of participants	5	3	2	1	11
Female, N (%)	2 (40)	2 (67)	1 (50)	1 (100)	6 (54)
Age, mean (SD)	36.4 (10.5)	29.0 (6.08)	41.0 (4.24)	39.0 (-)	35.5 (8.56)
Vaccinated[a], N (%)	1 (20)	1 (33)	0 (0)	0 (0)	2 (18)
Latino, N (%)	0 (0)	1 (33)	0 (0)	0 (0)	1 (9)
Race					
Black or African American, N (%)	2 (40)	1 (33)	1 (50)	0 (0)	4 (36)
White, N (%)	3 (60)	2 (67)	1 (50)	1 (100)	7 (64)

a. Vaccinated against influenza in the past 6 months at the time of entering the quarantine facility.

Table 2. Donor Demographics for Cohorts 24b & 24c

	Cohort 24b	Cohort 24c	All
Number of participants	1	4	5
Female, N (%)	1 (100)	3 (75)	4 (80)
Age, mean (SD)	23.0 (-)	20.5 (0.577)	21.0 (1.22)
Vaccinated[a], N (%)	0 (0)	2 (50)	2 (40)
Latino, N (%)	0 (0)	2 (50)	2 (40)
Race			
Asian, N (%)	1 (100)	0 (0)	1 (20)
Black or African American, N (%)	0 (0)	2 (50)	2 (40)
White, N (%)	0 (0)	2 (50)	2 (40)

a. Vaccinated against influenza in the past 6 months at the time of entering the quarantine

facility.

Figures

Figure 1. Study design and timeline

(a) Schematic of the study workflow and exposure event room. (b) Timelines for cohorts 24b (started January 24, 2024) and 24c (started February 14, 2024). Shaded blocks indicate phases (Run-in, Donor exposure, Observation, Discharge, Follow-up). Arrows mark donor introductions (D24b-1 on 01/30; D24c-1 on 02/16, D24c-2 on 02/17, D24c-3&D24c-4 on 02/21).

Figure 2. Variations in indoor temperature, relative humidity, and CO_2 concentration in the exposure event room and hallway during cohorts.

(a) Cohort 24b (Jan 30–Feb 1, 2024); (b) Cohort 24c, first donor block (Feb 16–19, 2024); (c) Cohort 24c, second donor block (Feb 21–23, 2024). The left y-axis shows temperature (°C) and relative humidity (%); the right y-axis shows CO_2 concentration (ppm). Line plots show temperature (orange, solid), relative humidity (dark blue, solid), exposure event room CO_2 (green, dashed), hallway CO_2 (purple, dot-dashed). Yellow bands denote each exposure event windows; vertical ticks mark exposure start (red) and end (black). Temperature and humidity were maintained within stable ranges by the mechanical systems, as these parameters can influence virus stability. CO_2 concentration is a proxy for ventilation and a direct indicator of rebreathed air; levels increased during exposure events due to occupancy and slowly returned to background afterward, reflecting the low ventilation condition targeted in these experiments.

Figure 3. Viral RNA and infectious viral load in Donor samples

Violin plots depict the distribution of viral RNA and infectious (fluorescent focus unit, FFU) viral loads (log10 RNA copies and FFU) across four different sample types: breath aerosol <5 µm, breath aerosol ≥5 µm, mid-turbinate swabs (MTS), and saliva. RNA copy and FFU values are expressed as follows: per 30-minute sample for breath aerosols, per swab for MTS, and per mL for saliva. Negative samples were assigned a value of 1.

Figure 4. Donor sample viral RNA, infectious viral load, total symptom score and cough trajectories with timing of positive environmental samples.

Each individual plot shows one donor over their days in quarantine. Lines/points show RNA (solid) and FFU (dashed) for: breath aerosol <5 µm (solid circle, orange), breath aerosol ≥5 µm

(solid triangle, sky blue), mid-turbinate swab (MTS; solid square, green), and saliva (solid diamond, purple). Cough counts during 30-min breath sampling (dot-dash line, black, open circle) and self-reported total symptom score (dotted line, grey, open square) are overlaid and referenced to the right axis. Shaded bands mark environmental positives centered on the day that positives samples were detected: Ambient+ (light blue) and Ambient+ & Surface+ (yellow). Donors' samples were collected once per day, prior to any exposure events (on the afternoon or evening of admission and otherwise in the morning), ambient samples were collected during afternoon events and surface swabs at the end of each exposure event. RNA copy and FFU values are expressed as follows: per 30-minute sample for breath aerosols, per swab for MTS, and per mL for saliva. Negative samples were assigned a value of 1.

Figure 5. Symptom severity and progression in Donors during quarantine
(a) Heatmap shows the maximum individual symptom scores reported by individual Donors. The color intensity represents the symptom severity, with scores ranging from 0 to 3. Symptoms are listed along the x-axis, and Donors are on the y-axis. Columns are grouped by domains: Upper respiratory (running nose, stuffy nose, sneeze, sore throat, earache), Lower respiratory (chest tightness, shortness of breath, cough), and Systemic (malaise, headache, muscle & joint ache, chills, feverish).
(b) Line plots present total symptom scores and symptom group scores (upper respiratory, lower respiratory, and systematic symptoms) over time for each individual Donor. The x-axis represents cohort timelines, and the y-axis indicates the sum of each symptom group scores.

Figure 6. Symptom severity and progression in Recipients during quarantine
(a) Heatmap shows the maximum individual symptom scores reported by individual Recipients. The color intensity represents the symptom severity, with scores ranging from 0 to 3. Symptoms are listed along the x-axis, and Recipients are on the y-axis.
(b, c) Line plots present total symptom scores over time for Recipients. (b) shows data for the Recipients in cohort 24b, while (c) shows data for those in cohort 24c. The x-axis represents the timeline, with the yellow-shaded areas indicating periods of Donor quarantine. Each subplot corresponds to an individual Recipient, with blue lines (circle) representing the control group and green lines (triangle) representing the intervention group.

Figure 7: HAI titers over time for Donors and Recipients in Cohort 24b

HAI titers are shown for Donors (solid lines, star symbols), Vaccinated Recipients (dot-dashed lines, filled triangles), and Unvaccinated Recipients (dot-dashed lines, open circles) at four time points: T0 (Recipient screening), T1 (Admission), T2 (Discharge), and T3 (Follow-up). Virus targets are color-coded: A/Victoria/4897/22 (H1N1, blue), A/Darwin/6/21 (H3N2, green), and B/Austria/1359417/21 (red). Each facet represents an individual study participant.

Figure 8: HAI titers over time for Donors and Recipients in Cohort 24c

HAI titers are shown for Donors (solid lines, star symbols) and Unvaccinated Recipients (dot-dashed lines, open circles) at four time points: T0 (Recipient screening), T1 (Admission), T2 (Discharge), and T3 (Follow-up). Virus targets are color-coded: A/Victoria/4897/22 (H1N1, blue), A/Darwin/6/21 (H3N2, green), and B/Austria /1359417/21 (red). Each facet represents an individual study participant.